Skip to main content

Antimicrobial growth promoters approved in food-producing animals in South Africa induce shiga toxin-converting bacteriophages from Escherichia coli O157:H7.

Abstract

In this study, four antimicrobial growth promoters, including virginiamycin, josamycin, flavophospholipol, poly 2-propenal 2-propenoic acid and ultraviolet light, were tested for their capacity to induce stx-bacteriophages in 47 Shiga toxin-producing E. coli O157:H7 isolates. Induced bacteriophages were characterized for shiga toxin subtypes and structural genes by PCR, DNA restriction fragment length polymorphisms (RFLP) and morphological features by electron microscopy. Bacteriophages were induced from 72.3% (34/47) of the STEC O157:H7 isolates tested. Bacteriophage induction rates per induction method were as follows: ultraviolet light, 53.2% (25/47); poly 2-propenal 2-propenoic acid, 42.6% (20/47); virginiamycin, 34.0% (16/47); josamycin, 34.0% (16/47); and flavophospholipol, 29.8% (14/47). A total of 98 bacteriophages were isolated, but only 59 were digestible by NdeI, revealing 40 RFLP profiles which could be subdivided in 12 phylogenetic subgroups. Among the 98 bacteriophages, stx2a, stx2c and stx2d were present in 85.7%, 94.9% and 36.7% of bacteriophages, respectively. The Q, P, CIII, N1, N2 and IS1203 genes were found in 96.9%, 82.7%, 69.4%, 40.8%, 60.2% and 73.5% of the samples, respectively. Electron microscopy revealed four main representative morphologies which included three bacteriophages which all had long tails but different head morphologies: long hexagonal head, oval/oblong head and oval/circular head, and one bacteriophage with an icosahedral/hexagonal head with a short thick contractile tail. This study demonstrated that virginiamycin, josamycin, flavophospholipol and poly 2-propenal 2-propenoic acid induce genetically and morphologically diverse free stx-converting bacteriophages from STEC O157:H7. The possibility that these antimicrobial growth promoters may induce bacteriophages in vivo in animals and human hosts is a public health concern. Policies aimed at minimizing or banning the use of antimicrobial growth promoters should be promoted and implemented in countries where these compounds are still in use in animal agriculture.

Introduction

Shiga toxin-producing Escherichia coli O157:H7 (STEC) causes foodborne disease in humans characterized by watery or bloody diarrhea. In 5–10% of patients, human STEC disease has been associated with complications including hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS). Ruminants, including cattle, sheep and goats are the main reservoirs of STEC [1]. Humans acquire STEC infections by ingesting STEC-contaminated meat and dairy products, water or vegetables [2,3,4]. STEC can be also transmitted from person-to-person and by contact with infected ruminants [5].

The major virulence factors of STEC are two antigenically distinct bacteriophages-encoded Shiga toxins: stx1 and stx2, with various genetic variants including four stx1 (stx1a, stx1c, stx1d and stx1e) and 15 stx2 (stx2a, stx2b, stx2c, stx2d, stx2e, stx2f, stx2g, stx2h, stx2i, stx2j, st2k, st2l, stx2m, stx2n and stx2o) subtypes [3, 6, 7]. The genetic structure of shiga toxin-converting bacteriophages (also termed stx-converting bacteriophages or stx-phages) is similar to that of lambdoid bacteriophages, with immediate early, delayed and late phase transcribed genes [8]. Bacteriophage genomes are composed of structural genes which encode proteins responsible for capsid, tail, tail fibers and spike formation. In addition, a number of structural genes encode proteins that regulate virion replication, assembly and release, and shiga toxin expression. Important structural genes include Q, N and N2, which encode transcriptional antiterminator and late antiterminator proteins, respectively [9, 10]. Additional genes located upstream of the Q antiterminator include the cI repressor and P, which are responsible for phage immunity and DNA replication, respectively [11, 12].

Previously, it was shown that antimicrobial growth promoters which are supplemented to animal feed at subinhibitory concentrations induce lysogenic stx-converting bacteriophages in the STEC chromosome [13]. Bacteriophage induction occurs when antimicrobials damage DNA and activate the bacterial SOS response, which interferes with virion replication [14, 15]. At the molecular level, activation of the SOS system leads to derepression of the bacteriophage repressor (CI), which triggers transcription of genes involved in bacteriophage assembly, bacteriolysis and release of free virion particles from STEC [16, 17]. This phenomenon is considered the main driver of STEC emergence and evolution [8, 16]. Clinically, the use of antimicrobials for treatment of STEC disease in humans has been linked to induction of stx-converting bacteriophages with subsequent increase in Stx production and severe STEC disease in humans [18,19,20,21,22].

Although antimicrobial growth promoters have been banned in the European Union since 2006 [23], these compounds are still used as in-feed additives for livestock growth promotion in many countries around the world, including South Africa. In South Africa, 29% of antimicrobials that are approved for use in livestock growth promotion include compounds banned in the European Union, such as virginiamycin, josamycin, flavophospholipol and poly 2-propenal 2-propenoic acid [24]. Poly 2-propenal 2-propenoic acid cross-links and inactivates surface lipoproteins in the bacterial cell wall leading to bacterial death by lysis [25]. Both virginiamycin, a streptogramin, and josamycin, a second-generation macrolide, inhibit protein synthesis by binding to the 50 S subunit of the bacterial ribosome [26,27,28]. Flavophospholipol is a glycolipid antibiotic which blocks bacterial cell wall synthesis by suppressing peptidoglycan glycosyltransferases [29].

In this study, the capacity of virginiamycin, josamycin, flavophospholipol, poly 2-propenal 2-propenoic acid, and ultraviolet (UV) light to induce stx-converting bacteriophages from STEC O157:H7 was investigated. The four antimicrobial compounds have never been evaluated for their capacity to induce stx-converting bacteriophages. Bacteriophage induction assays were conducted in vitro on a collection of 47 STEC O157:H7 isolates. Released bacteriophages were further characterized for possession of structural and stx-encoding genes, morphology and restriction fragment length polymorphisms (RFLPs).

Results

STEC O157:H7 characteristics and bacteriophage induction rates

Bacteriophages were induced from 34/47 (72.3%) STEC O157:H7 isolates tested. The rates of bacteriophage induced per induction method from the 47 STEC O157:H7 isolates were as follows (Fig. 1 and Table 1and Supplementary Material TableS1): UV, 53.2% (25/47); poly 2-propenal 2-propenoic acid, 42.6% (20/47); josamycin, 34.0% (16/47); virginiamycin, 34.0% (16/47); and flavophospholipol, 29.8% (14/47). Only 14.9% (7/47) of STEC O157:H7 isolates tested released bacteriophages spontaneously.

Fig. 1
figure 1

Stx-converting bacteriophages induction rates by UV and four antimicrobial growth promoters

Fig. 2
figure 2

Bacteriophages plaques on agar plates after induction by virginiamycin

Bacteriophage productivity scores per induction method

Table 1 Fig. 2. Bacteriophages productivity scores per induction method among the 47 STEC O157:H7 isolates

Distribution of bacteriophage-encoded genes

A total of 98 stx-converting bacteriophages were isolated and further genotyped for stx-encoding and structural genes (Supplementary Material- TableS1). PCR genotyping revealed that all induced bacteriophages were stx2 positive. Overall, the following rates of stx-encoding and structural genes were obtained from the 98 induced bacteriophages: stx2, 85,7%, (84/98); stx2c, 94,9% (93/98); and stx2d, 36.7%, (36/98). P, 96,9% (95/98); Q, 82.7%, (81/98); CIII, 69,4, (68/98); N1, 40,8 (40/98); N2, 60,2, (59/08); IS1203/Integrase, 73,5 (72/98) (Supplementary Material- Table S1).

Bacteriophages productivity scores and presence of stx-encoding and structural genes in induced bacteriophages per induction method are depicted in Figs. 3 and 4; Table 1 and Supplementary Materials TableS1. Among the 25 bacteriophages which were induced by UV, 76% (19/25) were stx2 positive, 84% (21/25) carried stx2c, and 8% (2/25) carried stx2d. The following rates were obtained for genes coding for bacteriophage structural genes: P, 96% (24/25); Q, 84% (21/25); CIII, 48% (12/25); N1, 12% (3/25); N2, 8% (2/25); and IS1203 (integrase), 64% (16/25).

Among the 20 bacteriophages induced by poly 2-propenal 2-propenoic, bacteriophage-encoded genes were observed at the following rates: stx2, 75% (15/20); stx2c, 100% (20/20), stx2d, 10% (2/20); P, 95% (19/20); Q, 65% (13/20); CIII, 30% (6/20); N1, 45% (9/20); N2, 75% (15/20); IS1203, 65% (13/20).

The 16 josamycin-induced bacteriophages revealed the following proportions of genes: stx2, 100% (16/16); stx2c, 100% (16/16), stx2d, 87.5% (14/16); P, 93.8% (15/16); Q, 81.3% (13/16); CIII, 100% (16/16); N1, 62.5% (10/16); N2, 68.8% (11/16); IS1203 (integrase), 75% (12/16).

Virginiamycin-induced bacteriophages carried genes at the following rates: stx2, 93.8% (15/16); stx2c, 100% (16/16); stx2d, 37.5% (6/16); P, 100% (16/16); Q, 100% (16/16); CIII, 93.8% (15/16); N1, 43.8% (7/16); N2, 81.3% (13/16); and IS1203 (integrase), 68.8% (11/16). The 14 bacteriophages that were induced by flavophospholipol had the following genes: stx2, 85.7% (12/14); stx2c, 100% (14/14); stx2d, 35.7% (5/14); P, 100% (14/14); Q, 78.6% (11/14); CIII, 92.9% (13/14); N1, 35.7% (5/14); N2, 92.9% (13/14); and IS1203 (integrase), 92.9% (13/14). Among the 7 spontaneously induced bacteriophages, the following rates of genes were recorded: stx2, 100% (7/7); stx2c, 100% (7/7); stx2d, 100% (7/7); P, 100% (7/7); Q, 100% (7/7); CIII, 85.7% (6/7); N1, 85.7% (6/7); N2, 71.4% (5/7); and IS1203 (integrase), 100% (7/7).

Fig. 3
figure 3

Distribution of structural genes encoded among on bacteriophages induced with different methods

Fig. 4
figure 4

Distribution of stx2 subtypes among induced bacteriophages

Restriction fragment length polymorphism of bacteriophage DNA

Bacteriophage DNA was digested using the restriction enzyme NdeI (Fig. 5), and a dendrogram was generated from RFLP digest gel images. Among the 98 induced bacteriophages, only 59 could be digested by NdeI. Analysis of the 59 RFLP profiles displayed 40 bacteriophage subtypes. The 40 subtypes could be assigned to 12 phylogenetic subgroups with a Dice similarity index ≥ 60% (Fig. 6). Among the 12 phylogenetic subgroups, three subgroups (9, 10 and 11) were each represented by one bacteriophage. Two subgroups (8 and 12) were represented by two bacteriophages each, three comprised 4 bacteriophages each (3, 6 and 7), one subgroup was represented by nine bacteriophages (subgroup 1), two subgroups comprised 10 bacteriophages each (subgroups 2 and 4) and one (subgroup 5) consisted of 11 bacteriophages.

Fig. 5
figure 5

Electrophoresis in a 0.8% agarose gel digestion by NdeI restriction enzyme of Stx bacteriophage DNA induced by flavophospholipol and isolated from cattle O157:H7 strains. M - molecular size markers. The right side of the figure shows marker band sizes. Bacteriophages 75 and 79 showed very faint bands

Fig. 6
figure 6

Dendogram depicting relatedness/diversity among bacteriophages generated from RFLP profiles by NdeI digestion

Morphological features and dimensions of bacteriophages

Electron microscopy revealed four morphologies: bacteriophages that possessed elongated icosahedral heads with long tails, oval heads with long tails and hexagonal heads with long tails and hexagonal heads with short thick contractile tail. All these bacteriophages lacked tail fibers (Fig. 7).

Fig. 7
figure 7

Electron micrographs of four bacteriophages. (A) Long hexagonal head with a long tail, (B) oval/circular head with a long tail. (C) Icosahedral/hexagonal head with a thick contractile tail. (D) Elongated (oblong) head with long tail. Bars = 200 nm

Discussion

In this study, UV and four antimicrobial promoters, including poly 2-propenal 2-propenoic acid, josamycin, virginiamycin and flavophospholipol were tested for their capacity to induce bacteriophages in 47 STEC O157:H7 isolates from humans, cattle and goats. The four antimicrobials are approved for livestock growth promotion in South Africa but have never been tested for their capacity to induce bacteriophages.

Overall, it was possible to induce bacteriophages in 72.3% of the STEC O157:H7 isolates using UV light and the four antimicrobial promoters tested including poly 2-propenal 2-propenoic acid, josamycin, virginiamycin and flavophospholipol. As expected, the highest number of bacteriophages (53.2%) was induced by UV irradiation. UV light is considered a standard and effective inducer of stx-converting bacteriophages [30,31,32,33]. Zhang et al. [34]. Zhang et al. [34] compared bacteriophage induction by UV irradiation and a number of antimicrobials and showed that UV irradiation induced bacteriophages in the highest number of STEC isolates.

All the four antimicrobial growth promoters which were tested in this study induced plaque-forming stx-converting bacteriophages (Fig. 2). However, bacteriophage induction rates and productivity scores were highly variable among induced STEC O157:H7 isolates. Poly 2-propenal 2-propenoic acid induced bacteriophages in the highest number of STEC O157:H7 (42.6%), followed by virginiamycin and josamycin (34,0%) and flavophospholipol (29.2%). This finding is consistent with other studies that have also observed variable bacteriophages induction capacity rates among antimicrobials [13, 19, 22, 35,36,37]. However, in contrast to previous studies that have shown that stx-converting bacteriophages are mainly induced by DNA-damaging antimicrobials that activate the SOS response [22, 35, 36, 38], this study demonstrated that bacteriophages could also be induced by protein (poly 2-propenal 2-propenoic acid, virginiamycin, josamycin) [25, 26, 28] and peptidoglycan synthesis (flavophospholipol) [29, 39] inhibiting antimicrobials. Previous studies have shown that antimicrobial agents that block bacterial cell wall or peptiglycan formation or protein synthesis either had no effect, suppressed or decreased stx-bacteriophage induction [35, 40,41,42]. While it remains unclear why there are differences in bacteriophages induction rates between this study and previous studies which used antimicrobials that inhibit protein and peptidoglycan synthesis capacity in bacterial hosts, variations in bacteriophages induction rates may have been influenced by the use of inadequate or suboptimal antimicrobial subinhibitory concentrations to induce bacteriophages in previous studies [26, 27, 29, 39]. Furthermore, the observed variations may be due to yet unexplained or unknown factors which are associated with intrinsic characteristics of the STEC O157:H7 isolates induced.

Similarly, as for bacteriophages induction rates, variations in bacteriophages productivity scores were also observed for different antimicrobials used to induce bacteriophages. The majority of isolates induced by josamycin and UV produced the highest number of bacteriophage plaques (more than 10 plaques/isolate). In contrast, the lowest bacteriophage productivity scores (≤ 5 plaques/isolate) were observed when poly 2-propenal 2-propenoic acid was used to induce bacteriophages, although this compound induced bacteriophages in the highest number of STEC O157:H7 isolates. According to Abedon and Culler, [43], during bacteriophage induction, high bacteriophages (plaque) productivity scores are a consequence of an optimal and long bacteriophage latent period, while low plaque productivity scores have been associated with a shorter bacteriophage latent period. Once again, while factors which influence variations in bacteriophage productivity scores cannot be explained, we suggest that bacteriophage productivity scores may also have been positively or negatively influenced by the use of nonptimal subinhibitory concentrations of antimicrobials used to induce bacteriophages.

It is difficult to compare our findings with other studies regarding the capacity of different antimicrobials to induce bacteriophages or influence virion productivity scores because previously similar bacteriophage induction studies were conducted on very small numbers of STEC isolates to allow valid comparisons with the our results [35, 40,41,42, 44]. Moreover, these investigations have yielded mixed results which cannot be compared with this study, depending on whether a direct or indirect method was used to measure stx-bacteriophage induction levels [35, 40,41,42, 44]. In addition, in this study, bacteriophage induction was assessed by the plaque assay technique, which is a direct method for measuring bacteriophage induction and productivity scores. This is unlike previous studies which demonstrated bacteriophage induction using indirect methods by measuring mRNA transcription levels, Stx expression levels or production of free Stx [19, 35, 45]. Differences in stx-bacteriophages induction rates and productivity scores among the STEC O157:H7 isolates tested may be a reflection of variations in STEC virulence capacity, toxin production levels and disease severity manifestations in human hosts, which can range from mild diarrhea to severe bloody diarrhea and complications such as HC and HUS.

Our results also showed that it was possible to induce stx-bacteriophages spontaneously in a small number of STEC O157:H7 isolates (14%), consistent with previous studies that have shown that stx-bacteriophages can be spontaneously induced from a small number of STEC O157:H7 strains [46, 47] under the influence of yet unknown environmental signals, sometimes independent of the RecA-dependent SOS response system [48]. Previous reports have shown that lysogens encoding stx1 or stx2 spontaneously released approximately 1 in 20 000–70 000 virion particles per cell generation [48, 49]. Bullwinkle et al., suggested that spontaneous induction occurs as a result of suboptimal concentrations of repressor needed to activate lytic functions in stx-bacteriophages [50, 51]. It appears that some stx-converting bacteriophages are evolutionarily selected for spontaneous induction in comparison to bacteriophages which require chemical or physical induction to be induced.

There were 27.7% of STEC O157:H7 isolates which did not induce any bacteriophages. STEC O157:H7 isolates that could not produce bacteriophages may have defective promoters that lack the switch from the lysogenic to the lytic state. Furthermore, bacteriophage induction failure and unsuccessful plaquing capacity may be ascribed to expression of colicins that are lethal to E. coli strains used for bacteriophage propagation [32]. In addition, some isolates may have not been able to produce bacteriophages because of an unsuitable, immune or insensitive bacteriophage propagation strain.

All 98 induced bacteriophages carried stx2, including 75% that possessed stx2c while a far lower number (36.7%) possessed stx2d. The high frequency of stx2/stx2c-encoding bacteriophages and a lower rate of stx2d-encoding virion particles was not surprising as these results corresponded to the original characteristics of STEC O157:H7 isolates induced in this study which have been reported elsewhere [52,53,54]. Higher induction rates of stx2 followed by stx2c-encoding bacteriophages and a lower number of stx2d-positive virion particles is consistent with previous studies which observed that stx2 and stx2c-encoding bacteriophages were more readily inducible in comparison to stx2d-carrying phages [47, 55, 56]. Furthermore, Fitzgerald et al., [57] reported that stx2-encoding bacteriophages were more frequently induced from STEC O157:H7 than stx2c. Also, previous reports on the molecular epidemiology of clinical STEC isolates have associated STEC strains that possess stx2 and stx2c with a higher likelihood of severe disease occurrence in humans including HUS [58, 59]. Moreover, a finding of lower rates of stx2d-encoding bacteriophages was consistent with Gobius et al. [56] who observed that stx2d-encoding bacteriophages may be noninducible because they are carried on cryptic prophages remnants that lack genes responsible for activation from lysogeny to the lytic replicative cycle.

Out of the 98 induced bacteriophages, only 59 were digestible with the NdeI restriction enzyme, while the remaining 39 could not be cut by NdeI. Analysis of restriction fragment length polymorphism patterns showed that the 59 bacteriophage restriction profiles belonged to 12 major subgroups, reflecting the diversity (Dice similarity index ≥ 60%) among stx-converting STEC O157:H7 bacteriophages. Previous reports have also shown that stx-converting bacteriophages are very heterogeneous [12, 31, 60, 61]. Furthermore, a small portion of bacteriophages which were induced by poly 2-propenal 2-propenoic acid (cluster 2) and leucomycin (cluster 5) induction displayed identical (100%) restriction patterns. There was also a cluster of very closely related bacteriophages which were induced by flavophospholipol (cluster 1). Bacteriophages that clustered together or closely related were released from STEC O157:H7 isolates that originated from the same farm, suggesting the circulation of identical or closely related STEC O157:H7 strains and bacteriophages on farms where these isolates were collected.

Genotyping revealed that the majority of bacteriophages carried the P (attachment), Q (antiterminator), CIII (repressor) N(1) and IS1234 (integrase) genes, while the N(2) gene, which also codes for integrase was amplified in only 40.8% of bacteriophages, independent of the bacteriophage induction method. This is consistent with previous studies which observed that structural genes are mostly conserved among stx-converting bacteriophages of STEC O157:H7 which usually share a common genetic regulatory system [9, 55, 60, 62, 63]. However, while structural genes of stx-converting bacteriophages are mostly conserved, variations among these genes have been observed depending on the origin of the STEC O157:H7 isolates harboring them, as previously shown in studies which compared fly with cattle isolates [62] and clinical versus bovine STEC strains [63]. The presence of structural genes among stx-bacteriophages may also vary depending on the subtype of the gene (Q21 vs. Q33) [63] or whether a particular gene subtype is truncated or complete [64]. Furthermore, Llarena et al., (2021) [65] reported new non-lambdoid stx-converting bacteriophages which carried yet undescribed novel sequences of P replication initiation genes.

Electron microscopy revealed four main groups of stx-converting bacteriophages morphologies including three which all had a long tail with the following representative head shapes: a long hexagonal head, oval/circular head, and elongated (oblong/prolate) head [31, 66, 67]. A fourth group of bacteriophages had an icosahedral/hexagonal head with a short thick contractile tail. The morphological features of bacteriophages which were observed in this study agreed with previous studies, which found that most stx-converting bacteriophages either had elongated or oval heads with long tails or regular hexagonal heads with short tails [31, 66, 67].

To our knowledge, this is the first study reporting on the capacity of virginiamycin, josamycin, flavophospholipol and poly 2-propenal 2-propenoic acid to induce bacteriophages from STEC O157:H7 isolates. Our results demonstrated that these four antimicrobials induce stx-converting bacteriophages, which are genetically and morphologically diverse. The induced stx-bacteriophages encoded stx2 and stx2c mostly and stx2d to a lesser extent. The use of these antimicrobial promoters as in-feed additives in South Africa and other countries around the world may be contributing to STEC emergence and expansion and evolution of new STEC by converting naïve E. coli into STEC through lateral gene transfer. This is a public health concern that warrants the formulation of evidence-based policies aimed at stimulating the prudent use of antimicrobials in livestock husbandry. Finding alternative antimicrobial promoters that do not compromise public health or an altogether ban of these compounds in South Africa and other countries where they are still used in animal Agriculture is recommended.

Materials and methods

Bacterial strains

A total of 47 STEC O157:H7 isolates were used for the induction of stx-converting bacteriophages. The STEC O157:H7 isolates included 34 cattle (25 beef + 9 dairy), six human and seven goat isolates. Before conducting bacteriophage induction studies, the 47 isolates were reconfirmed as STEC O157:H7 [68, 69] and screened for stx1, stx2, stx2c and stx2d by PCR [70, 71]. Briefly, multiplex polymerase chain reaction (mPCR) was performed to detect stx1 and stx2 in the STEC isolates using previously described primers and cycling conditions [70]. The virulence characteristics of the STEC isolates used for bacteriophages induction were reported in previous studies [52,53,54].

Bacteriophage induction with UV light

UV light was used as the reference standard bacteriophage induction method against which bacteriophage induction by antimicrobial growth promoters was compared. Bacteriophage induction with UV light irradiation was carried out according to previously published protocols [31]. Briefly, before bacteriophage induction assays, frozen STEC O157:H7 cultures were streaked on Luria Bertani (LB) agar (10 g tryptone, 5 g yeast extract, 10 g/L NaCl) and incubated at 37 °C overnight to obtain pure single colonies of STEC O157:H7. A single colony of STEC O157:H7 was added to a 250 ml Erlenmeyer baffled base culture flask (BD Biosciences, Erembodegem, Belgium) containing 45 ml of modified LB broth (10 g tryptone, 5 g yeast extract, 2.5 g/L NaCl and 0.01 M CaCl2). The broth was incubated at 37 °C with shaking at 200 rpm for 4 h to attain exponential growth. After four hours of incubation, the bacterial culture was centrifuged at 4000 rpm for 45 min. The pellet was suspended in 5 ml of 0.01 M CaCl2 and transferred onto a glass petri dish. Thereafter, bacteriophage induction was carried out by UV irradiation of the STEC O157:H7 strains according to a previously described protocol [31]. Briefly, the petri dish containing the bacterial suspension was placed inside a biosafety cabinet (Esco AC2-4S1, South Africa) under a UV lamp at 40 cm (Esco, UV-30 A, South Africa). The front movable window was covered with aluminum foil to create a dark chamber. Bacteriophage induction was performed by irradiating the bacterial suspension for 120 s with UV light. The UV light wavelength was 254 nm. The irradiated bacterial suspension was transferred into a sterile 250 mL Erlenmeyer baffled base culture flask (BD Biosciences, Erembodegem, Belgium) containing 45 mL of modified LB broth and incubated at 37 °C with shaking (200 rpm) overnight. The overnight culture was centrifuged at 4000 rpm for 45 min, and the supernatant was filtered in a 50 ml centrifuge tube through a 0.45-µm pore-size membrane. Two to three drops of chloroform were added to the filtrate. The filtrate was stored at 4 °C until further processing.

Bacteriophage induction with antimicrobial growth promoters

Four antimicrobial growth promoters were tested for their capacity to induce bacteriophages, including josamycin (leucomycin), virginiamycin, flavophospholipol and poly 2-propenol 2-propenoic acid (acrolein). All antimicrobials were supplied by Merck (Sigma‒Aldrich), South Africa, except for flavophospholipol, which was kindly donated by V-Tech Pty (Ltd), South Africa. Before bacteriophage induction, subinhibitory concentrations (SICs) of virginiamycin, josamycin (leucomycin A3), flavophospholipol and poly 2-propenal, 2-propenoic acid (acrolein) were determined based on previously published E. coli minimum inhibitory concentrations (MICs) [25, 72,73,74]. Bacteriophage induction using antimicrobials was similar to U.V. induction, with slight modifications. Briefly, STEC O157:H7 isolates were cultured in 45 ml of modified LB broth for 4 h with shaking at 200 rpm at 37 °C to attain the exponential growth phase. After 4 h, the exponential growing culture was centrifuged at 4000 X g for 5 min, the supernatant was discarded, and the bacterial pellet was suspended in 5 ml of a 0.01 CaCl2 solution. Bacteriophage induction was performed by adding SICs of antimicrobials to the 5 ml bacterial suspension: virginiamycin (2 µg/mL) [72], josamycin (128 µg/mL) [73] (flavophospholipol (64 µg/mL) [74] and poly 2-propenal 2-propenoic acid (3 µg/mL) [25]. The suspension was added to 45 ml of modified LB and incubated for 16-24 h with shaking at 200 rpm at 37 °C. After incubation, induced cultures were centrifuged at 4000 X g for 45 min, and the supernatant was filtered through a 0.45-µm pore-size membrane. Two to three drops of chloroform were added to the filtrate, which was stored at 4 °C until further processing. Spontaneous bacteriophage induction was also tested by culturing bacteria in modified LB broth for 20 h at 37 °C with shaking at 200 rpm followed by centrifugation of the broth at 4000 X g for 45 min followed by filtration of the supernatant through a 0.45-µm pore-size membrane. Two to three drops of chloroform were added to the filtrate which was stored at 4 °C, until further processing.

Bacteriophage propagation.

The double-layer agarose plaque assay technique for isolation and enumeration of phage ʎ was used to propagate bacteriophages and isolate plaques [75]. Briefly, 100 µL of the supernatant of the induced culture filtrate was mixed with 100 µL of 0.01 M CaCl2 and 100 µL of an overnight culture of the E. coli K-12 MC1061 bacteriophage propagation strain. The mixture was incubated at 37 °C for 30 min to allow bacteriophage adsorption, gently mixed with 3 mL of soft agarose (100 mL of modified LB broth, 0.5 g agarose) and poured onto a petri dish containing 1.5% modified hard LB agarose (Modified LB, 1.2 g MgSO4.7H2O, 15 g agarose in 1 L of H2O). The overlay soft agarose was allowed to solidify and incubated at 37 °C overnight while being monitored for plaque formation and productivity for up to 48 h. To rank the different levels of plaque productivity, a scoring system based on the number of plaque-forming units (PFUs) on agarose plates was applied as follows: +3 > 10 plaques; +2 = 5 to 10 plaques; +1 < 5 plaques; and + 0 no plaques .

Bacteriophage isolation

Single plaques were harvested from each plate showing plaques by aspirating a single plaque from the surface of the double layer agarose using a sterile glass Pasteur pipette. Aspirated plaques were individually suspended in Eppendorf tubes containing 500 µL of 0.01 M CaCl2 solution. A 100 µL aliquot of the plaque suspension was mixed with 100 µL of 0.01 M CaCl2 and 100 µL of the overnight culture of E. coli K-12 strain MC1061 and incubated for 30 min. The solution was gently mixed with 3 mL of soft agar, poured onto hard agar for bacteriophage propagation and incubated overnight at 37 °C. Bacteriophages were collected by pouring 5 mL of SM buffer solution (5.8 g NaCl, 2 g MgSO4.7H2O, 50 mL of 1 M Tris-Cl [pH 7.5], 5 mL of 2% gelatin, 1 L of H2O) onto petri dishes showing plaques. To obtain an adequate bacteriophage titer for DNA extraction, one plaque was multiplied on five petri dishes. Bacteriophage collection was carried out by pouring SM buffer (100 mM sodium chloride, 10 mM magnesium sulfate, 50 mM Tris-HCl, pH 7.5 and 0.01% (w/v) gelatin) on petri dishes showing plaques. To dislodge bacteriophages from the soft agar, the petri dishes were placed on a platform shaker (FMH Electronics, South Africa) and then incubated with soft shaking for 24–48 h at 4 °C. Bacteriophages were harvested by scratching off the top soft agarose from the hard agar and transferring the soft agar/SM buffer suspension mixture to a 50 mL centrifuge tube. Soft agar/SM buffer suspensions from a common single plaque were pooled in a 50 mL tube to obtain an adequate phage titer and centrifuged at 4000 X g for 30 min. The supernatant was filtered using a 0.45-µm pore-size membrane and transferred into a sterile 50 mL tube. To eliminate any probable residual bacterial contamination, two to three drops of chloroform were added to the bacteriophage filtrate, which was stored at 4 °C.

Bacteriophage DNA Extraction

DNA was extracted from bacteriophage lysate filtrates using the Qiagen Plasmid Midi Kit (Qiagen, Hilden, Germany) supplementary protocol for isolation of single-stranded DNA from M13 phage, according to the manufacturer’s instructions. The protocol is based on inactivation of bacterial DNA and RNA in a bacteriophage lysate with DNase and RNase, respectively, followed by precipitation of bacteriophage particles with 30% polyethylene glycol 8000 (Merck, South Africa), lysis of bacteriophages to release DNA, several DNA washings, DNA binding to an anion-exchange resin, DNA elution and precipitation and solution of the precipitated DNA in TE buffer (10 mM Tris, 1 mM EDTA, pH 8).

Genetic characterization of induced bacteriophages from STEC O157:H7

PCR was used to screen bacteriophage DNA for genes encoding shiga toxins (stx1, stx1c, stx1d, stx2, stx2c and stx2d) and bacteriophage structural genes (P, Q, CIII, N1, N2 and IS1203/integrase) [17, 60, 76]. In addition, to ensure that bacteriophage DNA was not contaminated with STEC bacterial chromosomal DNA, bacteriophage DNA was screened for the chromosomally encoded eaeA and hlyA genes [70]. The PCRs consisted of 25 µL containing 2.5 µL of 10X Thermopol reaction buffer, 2.0 µL of 2.5 mM dNTPs (deoxynucleotide triphosphates), 0.25 µL of 100 mM MgCl2, 0.6 µL of each primer (10 µM final concentration), 1 U of Taq DNA Polymerase and 5 µL of DNA template. All PCR reagents were procured from New England BioLabs (NEB, Ipswich, MA, USA) except for the primers, which were supplied by Inqaba Biotec (Pretoria, South Africa). DNA from the EDL933 (E. coli 0157:H7) strain and sterile molecular grade water were used as positive and negative controls, respectively, in all PCRs.

Restriction fragment length polymorphism profiling

RFLP profiling (RFLP) of bacteriophage DNA was carried out by digesting 5 µL of bacteriophage DNA with the NdeI restriction enzyme (New England BioLabs, Ipswich, MA, USA) according to the manufacturer’s instructions. Bacteriophage DNA was separated by electrophoresis in a 0.8% agarose gel, stained with ethidium bromide (0.5 µg/ml) and visualized with UV light in a Gel Doc system (Bio-Rad, USA). Bionumerics software (Applied Maths, Sint Martens-Latem, Belgium) was used to analyze RFLP patterns and construct dendrograms based on the Dice similarity index (complete linkage, optimization, 1.5%; position tolerance 1.5) and the unweighted pair group method with arithmetic mean (UPGMA).

Determination of bacteriophage morphology by electron microscopy

For morphological characterization of bacteriophages, bacteriophages were negatively stained with 3% phosphotungstic acid and examined by electron microscopy (EM). Briefly, a 1 mL suspension of phage supernatant was centrifuged in a Sigma 1–16 ultracentrifuge for 45 min, and the pellet was resuspended in sterile molecular grade water and a drop of the suspension deposited on a 300-mesh formvar-coated copper grid. The grid was negatively stained with 3% phosphotungstic acid and examined at 80 kV with a Philips CM10 transmission electron microscope at the EM Unit, Department of Anatomy and Physiology, Faculty of Veterinary Science, University of Pretoria.

References

  1. Gyles CL. Shiga toxin-producing Escherichia coli: an overview. J Anim Sci. 2007;85(13 Suppl):E45–62. https://doi.org/10.2527/jas.2006-508.

    Article  CAS  PubMed  Google Scholar 

  2. Feng P. Shiga Toxin-Producing Escherichia coli (STEC) in Fresh Produce-A Food Safety Dilemma. Microbiol Spectr. 2014;2(4):EHEC–0010. https://doi.org/10.1128/microbiolspec.EHEC-0010-2013.

    Article  CAS  PubMed  Google Scholar 

  3. Panel EFSABIOHAZ, Koutsoumanis K, Allende A, Alvarez-Ordónez A, Bover-Cid S, Chemaly M et al. Pathogenicity assessment of Shiga toxin-producing Escherichia coli (STEC) and the public health risk posed by contamination of food with STEC. Microbiol Spectr.2(3): EHEC-0001-2013. https://doi.org/10.2903/j.efsa.2020.5967.

  4. Beutin L, Fach P. Detection of Shiga toxin-producing Escherichia coli from nonhuman sources and strain typing. Enterohemorrhagic Escherichia coli and other Shiga Toxin-Producing E coli. Microbiol Spectr. 2014;2(3):EHEC–0001. https://doi.org/10.1128/microbiolspec.EHEC-0001-2013.

    Article  CAS  Google Scholar 

  5. Heiman KE, Mody RK, Johnson SD, Griffin PM, Gould LH. Escherichia coli O157 outbreaks in the United States, 2003–2012. Emerg Infect Dis. 2015;21(8):1293–301. https://doi.org/10.3201/eid2108.141364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gill A, Dussault F, McMahon T, Petronella N, Wang X, Cebelinski E, et al. Characterization of atypical Shiga toxin gene sequences and description of Stx2j, a new subtype. J Clin Microbiol. 2022;60(3):e02229–21. https://doi.org/10.1128/jcm.02229-21.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lindsey RL, Prasad A, Feldgarden M, Gonzalez-Escalona N, Kapsak C, Klimke W, et al. Identification and characterization of ten Escherichia coli strains encoding Novel Shiga Toxin 2 subtypes, Stx2n as Well as Stx2j, Stx2m, and Stx2o, in the United States. Microorganisms. 2023;11(10):2561. https://doi.org/10.3390/microorganisms11102561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rodríguez-Rubio L, Haarmann N, Schwidder M, Muniesa M, Schmidt H. Bacteriophages of Shiga toxin-producing Escherichia coli and their contribution to pathogenicity. Pathogens. 2021;10(4):404. https://doi.org/10.3390/pathogens10040404.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Unkmeir A, Schmidt H. Structural analysis of phage-borne stx genes and their flanking sequences in Shiga toxin-producing Escherichia coli and Shigella dysenteriae type 1 strains. Infect Immun. 2000;68(9):4856–64. https://doi.org/10.1128/iai.68.9.4856-4864.2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yokoyama K, Makino K, Kubota Y, Watanabe M, Kimura S, Yutsudo CH, et al. Complete nucleotide sequence of the prophage VT1-Sakai carrying the Shiga toxin 1 genes of the enterohemorrhagic Escherichia coli O157: H7 strain derived from the Sakai outbreak. Gene. 2000;258(1–2):127–39. https://doi.org/10.1016/s0378-1119(00)00416-9.

    Article  CAS  PubMed  Google Scholar 

  11. Neely MN, Friedman DI. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol. 1998;28(6):1255–67. https://doi.org/10.1046/j.1365-2958.1998.00890.x.

    Article  CAS  PubMed  Google Scholar 

  12. Kruger A, Lucchesi PMA. Shiga toxins and stx phages: highly diverse entities. Microbiology. 2015;161:451–62. https://doi.org/10.1099/mic.0.000003.

    Article  CAS  PubMed  Google Scholar 

  13. Kohler B, Karch H, Schmidt H. Antibacterials that are used as growth promoters in animal husbandry can affect the release of shiga-toxin-2-converting bacteriophages and Shiga toxin 2 from Escherichia coli strains. Microbiology. 2000;146:1085–90. https://doi.org/10.1099/00221287-146-5-1085.

    Article  CAS  PubMed  Google Scholar 

  14. Little JW, Mount DW. The SOS regulatory system of Escherichia coli. Cell. 1982;29(1):11–22. https://doi.org/10.1016/0092-8674(82)90085-x.

    Article  CAS  PubMed  Google Scholar 

  15. Aksenov SV. Induction of the SOS response in ultraviolet-irradiated Escherichia coli analyzed by dynamics of LexA, RecA and SulA proteins. J Biol Phys. 1999;25:263–77. https://doi.org/10.1023/A:1005163310168.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Allison HE. Stx-phages: drivers and mediators of the evolution of STEC and STEC-like pathogens. Future Microbiol. 2007;2(2):165–74. https://doi.org/10.2217/17460913.2.2.165.

    Article  CAS  PubMed  Google Scholar 

  17. Smith DL, James CE, Sergeant MJ, Yaxian Y, Saunders JR, McCarthy AJ, Allison HE. Short-tailed stx phages exploit the conserved YaeT protein to disseminate Shiga toxin genes among enterobacteria. J Bacteriol. 2007;189(20):7223–33. https://doi.org/10.1128/jb.00824-07.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Matsushiro A, Sato K, Miyamoto H, Yamamura T, Honda T. Induction of prophages of enterohemorrhagic Escherichia coli O157: H7 with norfloxacin. J Bacteriol. 1999;181(7):2257–60. https://doi.org/10.1128/JB.181.7.2257-2260.1999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis. 2000;6(5):458–65. https://doi.org/10.3201/eid0605.000503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic–uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 Infections. New Engl J Med. 2000;342(26):1930–6. https://doi.org/10.1056/NEJM200006293422601.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis. 2000;181(2):664–70. https://doi.org/10.1086/315239.

    Article  CAS  PubMed  Google Scholar 

  22. Grif K, Dierich M, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998;17:761–6. https://doi.org/10.1007/s100960050181.

    Article  CAS  PubMed  Google Scholar 

  23. Castanon J. History of the use of antibiotic as growth promoters in European poultry feeds. Poult Sci. 2007;86(11):2466–71. https://doi.org/10.3382/ps.2007-00249.

    Article  CAS  PubMed  Google Scholar 

  24. Henton MM, Eagar HA, Swan GE, van Vuuren M, Part VI. Antibiotic management and resistance in livestock production. S Afr Med J. 2011;101(8):583–6.

    CAS  PubMed  Google Scholar 

  25. Murdoch AI, McCauley RD, Hampson DJ. Review of the efficacy and safety of poly (2-propenal, 2-propenoic acid): a Novel Antimicrobial Polymer. Thai J of Vet Med. 2007;37(4):9–17. https://doi.org/10.56808/2985-1130.2107.

    Article  Google Scholar 

  26. Lovmar M, Vimberg V, Lukk E, Nilsson K, Tenson T, Ehrenberg M. Cis-acting resistance peptides reveal dual ribosome inhibitory action of the macrolide josamycin. Biochimie. 2009;91(8):989–95. https://doi.org/10.1016/j.biochi.2009.05.002.

    Article  CAS  PubMed  Google Scholar 

  27. Butaye P, Devriese LA, Haesebrouck F. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin Microbiol Rev. 2003;16(2):175–. https://doi.org/10.1128/cmr.16.2.175-188.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li Q, Seiple IB. A concise route to virginiamycin M2. Tetrahedron. 2019;75(24):3309–18. https://doi.org/10.1016/j.tet.2019.04.060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Volke F, Waschipky R, Pampel A, Donnerstag A, Lantzsch G, Pfeiffer H, et al. Characterisation of antibiotic moenomycin a interaction with phospholipid model membranes. Chem Phys Lipids. 1997;85(2):115–23. https://doi.org/10.1016/s0009-3084(96)02649-7.

    Article  CAS  PubMed  Google Scholar 

  30. O’Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic Colitis or infantile diarrhea. Science. 1984;226(4675):694–6. https://doi.org/10.1126/science.6387911.

    Article  PubMed  Google Scholar 

  31. Karama M, Gyles CL. Characterization of verotoxin-encoding phages from Escherichia coli O103: H2 strains of bovine and human origins. Appl Environ Microbiol. 2008;74(16):5153–8. https://doi.org/10.1128/aem.00723-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Allison HE, Sergeant MJ, James CE, Saunders JR, Smith DL, Sharp RJ, et al. Immunity profiles of wild-type and recombinant Shiga-Like toxin-encoding bacteriophages and characterization of novel double lysogens. Infect Immun. 2003;71(6):3409–18. https://doi.org/10.1128/iai.71.6.3409-3418.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Osawa R, Iyoda S, Nakayama SI, Wada A, Yamai S, Watanabe H. Genotypic variations of Shiga toxin-converting phages from enterohaemorrhagic Escherichia coli O157: H7 isolates. J Med Microbiol. 2000;49(6):565–74. https://doi.org/10.1099/0022-1317-49-6-565.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang Y, Liao Y-T, Salvador A, Sun X, Wu VCH. Prediction, diversity, and genomic analysis of Temperate Phages Induced from Shiga Toxin-Producing Escherichia coli strains. Front Microbiol. 2020;10. https://doi.org/10.3389/fmicb.2019.03093.

  35. McGannon CM, Fuller CA, Weiss AA. Different classes of Antibiotics differentially Influence Shiga Toxin production. Antimicrob Agents Chemother. 2010;54(9):3790–8. https://doi.org/10.1128/aac.01783-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, et al. Effects of antibiotics on Shiga Toxin 2 production and bacteriophage induction by Epidemic Escherichia coli O104:H4 strain. Antimicrob Agents and Chemother. 2012;56(6):3277–82. https://doi.org/10.1128/aac.06315-11.

    Article  CAS  Google Scholar 

  37. Carter MQ, Pham A, Du W-X, He X. Differential induction of Shiga toxin in environmental Escherichia coli O145: H28 strains carrying the same genotype as the outbreak strains. Int J Food Microbiol. 2021;339. https://doi.org/10.1016/j.ijfoodmicro.2020.109029.

  38. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular shiga-like toxin 1. Infection. 1992;20(1):25–9. https://doi.org/10.1007/bf01704889.

    Article  CAS  PubMed  Google Scholar 

  39. Sugimoto A, Maeda A, Itto K, Arimoto H. Deciphering the mode of action of cell wall-inhibiting antibiotics using metabolic labeling of growing peptidoglycan in Streptococcus pyogenes. Sci Rep. 2017;7. https://doi.org/10.1038/s41598-017-01267-5.

  40. Yoh M, Frimpong EK, Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 1997;19(1):57–64. https://doi.org/10.1111/j.1574-695X.1997.tb01072.x.

    Article  CAS  PubMed  Google Scholar 

  41. Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2007;51(8):2837–41. https://doi.org/10.1128/aac.01397-06.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Pedersen MG, Hansen C, Riise E, Persson S, Olsen KEP. Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol. 2008;46(9):2987–91. https://doi.org/10.1128/jcm.00871-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Abedon ST, Culler RR. Optimizing bacterlophage plaque fecundity. J Theor biol. 2007;249(3):582–92. https://doi.org/10.1016/j.jtbi.2007.08.006.

    Article  CAS  PubMed  Google Scholar 

  44. Yoh M, Frimpong EK, Voravuthikunchai SP, Honda T. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157: H7. Can J Microbiol. 1999;45(9):732–9. https://doi.org/10.1139/cjm-45-9-732.

    Article  CAS  PubMed  Google Scholar 

  45. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, et al. Origins of the E. Coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med. 2011;365(8):709–17. https://doi.org/10.1056/NEJMoa1106920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Olavesen KK, Lindstedt B-A, Løbersli I, Brandal LT. Expression of Shiga toxin 2 (Stx2) in highly virulent stx-producing Escherichia coli (STEC) carrying different anti-terminator (q) genes. Microb Pathog. 2016;97:1–8. https://doi.org/10.1016/j.micpath.2016.05.010.

    Article  CAS  PubMed  Google Scholar 

  47. Bonanno L, Petit M-A, Loukiadis E, Michel V, Auvraya F. Heterogeneity in induction level, Infection ability, and morphology of Shiga Toxin-Encoding Phages (Stx Phages) from dairy and human shiga toxin-producing Escherichia coli O26:H11 isolates. Appl Environ Microbiol. 2016;82(7):2177–86. https://doi.org/10.1128/aem.03463-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Livny J, Friedman DI. Characterizing spontaneous induction of Stx encoding phages using a selectable reporter system. Mol Microbiol. 2004;51(6):1691–704. https://doi.org/10.1111/j.1365-2958.2003.03934.x.

    Article  CAS  PubMed  Google Scholar 

  49. Iversen H, L’Abée-Lund TM, Aspholm M, Arnesen LP, Lindbäck T, Commensal. E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction. Front cell infect microbiol. 2015;5:5. https://doi.org/10.3389/fcimb.2015.00005.

  50. Bullwinkle TJ, Koudelka GB. The lysis-lysogeny decision of bacteriophage 933 W: a 933 W repressor-mediated long-distance loop has no role in regulating 933 w PRM activity. J Bacteriol. 2011;193(13):3313–23. https://doi.org/10.1128/JB.00119-11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Colon MP, Chakraborty D, Pevzner Y, Koudelka GB. Mechanisms that determine the Differential Stability of stx + and stx – lysogens. Toxins (Basel). 2016;8(4):96. https://doi.org/10.3390/toxins8040096.

    Article  CAS  PubMed  Google Scholar 

  52. Karama M, Cenci-Goga BT, Malahlela M, Smith AM, Keddy KH, El-Ashram S, et al. Virulence characteristics and antimicrobial resistance profiles of shiga toxin-producing Escherichia coli isolates from humans in South Africa: 2006–2013. Toxins (Basel). 2019;11(7):424. https://doi.org/10.3390/toxins11070424.

    Article  CAS  PubMed  Google Scholar 

  53. Karama M, Mainga AO, Cenci-Goga BT, Malahlela M, El-Ashram S, Kalake A. Molecular profiling and antimicrobial resistance of Shiga toxin-producing Escherichia coli O26, O45, O103, O121, O145 and O157 isolates from cattle on cow-calf operations in South Africa. Sci Rep. 2019;9(1):11930. https://doi.org/10.1038/s41598-019-47948-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Malahlela MN, Cenci-Goga BT, Marufu MC, Fonkui TY, Grispoldi L, Etter E, et al. Occurrence, serotypes and virulence characteristics of Shiga-toxin-producing Escherichia coli isolates from goats on communal rangeland in South Africa. Toxins (Basel). 2022;14(5):353. https://doi.org/10.3390/toxins14050353.

    Article  CAS  PubMed  Google Scholar 

  55. Muniesa M, Blanco JE, De Simón M, Serra-Moreno R, Blanch AR, Jofre J. Diversity of stx 2 converting bacteriophages induced from Shiga-toxin-producing Escherichia coli strains isolated from cattle. Microbiology. 2004;150(9):2959–71. https://doi.org/10.1099/mic.0.27188-0.

    Article  CAS  PubMed  Google Scholar 

  56. Gobius KS, Higgs GM, Desmarchelier PM. Presence of activatable Shiga toxin genotype (stx 2d) in Shiga toxigenic Escherichia coli from livestock sources. J Clin Microbiol. 2003;41(8):3777–83. https://doi.org/10.1128/JCM.41.8.3777-3783.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Fitzgerald SF, Beckett AE, Palarea-Albaladejo J, McAteer S, Shaaban S, Morgan J, et al. Shiga toxin sub-type 2a increases the efficiency of Escherichia coli O157 transmission between animals and restricts epithelial regeneration in bovine enteroids. PLoS Pathog. 2019;15(10):e1008003. https://doi.org/10.1371/journal.ppat.1008003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producingEscherichia coli and Disease in humans. J Clin Microbiol. 1999;37(3):497–503. https://doi.org/10.1128/JCM.37.3.497-503.1999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Friedrich AW, Bielaszewska M, Zhang W-L, Pulz M, Kuczius T, Ammon A, Karch H. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002;185(1):74–84. https://doi.org/10.1086/338115.

    Article  CAS  PubMed  Google Scholar 

  60. Johansen BK, Wasteson Y, Granum PE, Brynestad S. Mosaic structure of shiga-toxin-2-encoding phages isolated from Escherichia coli O157: H7 indicates frequent gene exchange between lambdoid phage genomes. Microbiology. 2001;147:1929–36. https://doi.org/10.1099/00221287-147-7-1929.

    Article  CAS  PubMed  Google Scholar 

  61. Fagerlund A, Aspholm M, Wegrzyn G, Lindback T. High diversity in the regulatory region of Shiga toxin encoding bacteriophages. BMC Genomics. 2022;23(1). https://doi.org/10.1186/s12864-022-08428-5.

  62. Ahmad A, Zurek L. Evaluation of the anti-terminator Q933 gene as a marker for Escherichia coli O157: H7 with high Shiga toxin production. Curr Microbiol. 2006;53(4):324–8. https://doi.org/10.1007/s00284-006-0089-3.

    Article  CAS  PubMed  Google Scholar 

  63. LeJeune JT, Abedon ST, Takemura K, Christie NP, Sreevatsan S, Human. Escherichia coli O157: H7 genetic marker in isolates of bovine origin. Emerg Infect Dis. 2004;10(8):1482. https://doi.org/10.3201/eid1008.030784.

  64. Teel LD, Melton-Celsa AR, Schmitt CK, O’Brien AD. One of two copies of the gene for the activatable Shiga toxin type 2d in Escherichia coli O91: H21 strain B2F1 is associated with an inducible bacteriophage. Infect Immun. 2002;70(8):4282–91. https://doi.org/10.1128/iai.70.8.4282-4291.2002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Llarena A-K, Aspholm M, O’Sullivan K, Wêgrzyn G, Lindbäck T. Replication region analysis reveals non-lambdoid shiga toxin converting bacteriophages. Front Microbiol. 2021;12:640945. https://doi.org/10.3389/fmicb.2021.640945.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Aertsen A, Faster D, Michiels CW. Induction of Shiga toxin-converting prophage in Escherichia coli by high hydrostatic pressure. Appl Environ Microbiol. 2005;71(3):1155–62. https://doi.org/10.1128/aem.71.3.1155-1162.2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Muniesa M, de Simon N, Prats G, Ferrer D, Panella H, Jofre J. Shiga toxin 2-converting bacteriophages associated with clonal variability in Escherichia coli O157: H7 strains of human origin isolated from a single outbreak. Infect Immun. 2003;71(8):4554–62. https://doi.org/10.1128/iai.71.8.4554-4562.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Iguchi A, Iyoda S, Seto K, Morita-Ishihara T, Scheutz F, Ohnishi M, Pathogenic ECWGJ. Escherichia coli O-Genotyping PCR: a comprehensive and practical platform for molecular O serogrouping. J Clin Microbiol. 2015;53(8):2427–32. https://doi.org/10.1128/jcm.00321-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Banjo M, Iguchi A, Seto K, Kikuchi T, Harada T, Scheutz F, et al. Escherichia coli H-Genotyping PCR: a complete and practical platform for molecular H typing. J Clin Microbiol. 2018;56(6). https://doi.org/10.1128/jcm.00190-18.

  70. Paton AW, Paton JC. Detection and characterization of shiga toxigenic Escherichia coli by using multiplex PCR assays for stx(1), stx(2), eaeA, enterohemorrhagic E-coli hlyA, rfb(O111), and rfb(O157). J Clin Microbiol. 1998;36(2):598–602. https://doi.org/10.1128/jcm.36.2.598-602.1998.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, Karch H, et al. Multicenter evaluation of a sequence-based protocol for Subtyping Shiga Toxins and standardizing stx nomenclature. J Clin Microbiol. 2012;50(9):2951–63. https://doi.org/10.1128/jcm.00860-12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Jensen LB, Hammerum AM, Aarestrup FM. Linkage of vat (E) and erm (B) in streptogramin-resistant Enterococcus faecium isolates from Europe. Antimicrob Agents Chemother. 2000;44(8):2231. https://doi.org/10.1128/AAC.44.8.2231-2232.2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Yamaguchi T, Haruo Hayasaka H, Yoshida T, Matsushita A, Yamabe. Satoshi Ohshima. Macrolide antibiotics M-4365 produced by Micromonospora III. In vitro antimicrobialactivity of antibiotic M-4365G 2 (de-epoxy rosamycin). J Antibiot. 1978;31(5):433–40. https://doi.org/10.7164/antibiotics.31.433.

    Article  CAS  Google Scholar 

  74. Pfaller MA. Flavophospholipol use in animals: positive implications for antimicrobial resistance based on its microbiologic properties. Diagn Microbiol Infect Dis. 2006;56(2):115–21. https://doi.org/10.1016/j.diagmicrobio.2006.03.014.

    Article  CAS  PubMed  Google Scholar 

  75. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Molecular cloning: a laboratory manual, vol Ed. 2. 1989.

  76. Latala B, Obuchowski M, Wegrzyn G. Bacteriophage lambda cIII gene product has an additional function apart from inhibition of cII degradation. Virus Genes. 2001;22(2):127–32. https://doi.org/10.1023/a:1008146709982.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research was funded by the National Research Foundation (NRF) of South Africa (CSRP170528234222 and SARCHI COP Grant 120317), the South African Medical Research Council Self-Initiated Research (MRC/SIR 2017–2019), and UNICEF Future Africa-University of Pretoria One Health for Change research grants-2021.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization, M.K., M.N.M., A.K and N.N.F.N.; data curation, M.K, M.N.M. and N.N.F.N ; formal analysis, and N.N.F.N., M.K., and M.N.M.; funding acquisition, M.K., B.T.C.-G., E.E., L.G. and A.K.; investigation, M.K., M.N.M., M.C.M.; methodology, B.T.C.-G., M.N.M., T.Y.F. and. L.G.; resources, M.K., B.T.C.-G. and L.G.; Project administration, M.K.; supervision, M.K. and M.C.M. writing—original draft, M.K. and M.N.M. Writing—review and editing M.K., M.N.M. and M.C.M.

Corresponding author

Correspondence to Musafiri Karama.

Ethics declarations

Conflict of interest

None declared.

Ethics approval and consent to participate

The protocol for this study was approved by the Research and Animal Ethics Committees of the Faculty of Veterinary Science, University of Pretoria (REC108-21).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ngoma, N.F.N., Malahlela, M.N., Marufu, M.C. et al. Antimicrobial growth promoters approved in food-producing animals in South Africa induce shiga toxin-converting bacteriophages from Escherichia coli O157:H7.. Gut Pathog 15, 64 (2023). https://doi.org/10.1186/s13099-023-00590-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13099-023-00590-9

Keywords